Warner Pharmaceuticals: Voluntary disclosure of the company\'s participation in centralized drug procurement to win the bid
Voluntary disclosure of the announcement on the company\'s participation in centralized drug procurement to win the bid
Warner Pharmaceuticals Investor Relations Activity Record Form (December 25, 2024)
Warner Pharmaceuticals: Notice on Voluntary Disclosure of Subsidiary Pharmaceutical Subsidies\' Approval Notice for Marketing Applications
Warner Pharmaceuticals: SDIC Securities Co., Ltd.\'s inspection opinions on the adjustment of core technical personnel of Hunan Warner Pharmaceutical Co., Ltd.
China Investment Securities Co., Ltd.\'s inspection opinion on the adjustment of core technical personnel of Hunan Warner Pharmaceutical Co., Ltd.
Voluntary Disclosure Notice Regarding Subsidiary Pharmaceuticals Obtaining Approval Notice for Marketing Applications
Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders
Legal Opinion of Beijing Kangda Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Hunan Warner Pharmaceutical Co., Ltd.
Announcement of Resolutions of the First Interim Meeting of the Fourth Board of Directors
Announcement of Resolutions of the First Interim Meeting of the Fourth Board of Supervisors
Self-inspection report on the company\'s 2024 restricted stock incentive plan insider information insiders and incentive targets trading the company\'s stock
Announcement on the election of the chairman, vice chairman, special committee of the board of directors and the appointment of senior management, head of internal audit, and chief scientist
Announcement on the adjustment of the company\'s core technical personnel
Announcement on the election of the Chairman of the Supervisory Board
Warner Pharmaceuticals Investor Relations Activity Record Form (December 13, December 16, 2024)
Explanation and verification opinions of the Board of Supervisors on the Company\'s 2024 Restricted Stock Incentive Plan incentive list
2024 Third Extraordinary General Meeting of Shareholders Meeting Meeting Materials
Warner Pharmaceuticals Investor Relations Activity Record Form (December 6, 2024)
Warner Pharmaceuticals: Voluntary Disclosure Notice on Receiving the Summary Report of the Phase II Clinical Trial of Qianqing Granules